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Abstract: Sunitinib (Su) is a tyrosine kinase inhibitor with antiangiogenic and antineoplastic effects
that is recommended therapy for renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic
neuroendocrine tumors. Arterial hypertension is one of the adverse effects observed in the treatment
with Su. The aim of this work was to deepen our understanding of the underlying mechanisms
involved in the development of this side effect. Studies on endothelial function, vascular remodeling
and nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase) system were carried
out in thoracic aortas from rats treated with Su for three weeks. Animals subjected to Su treatment
presented with increased blood pressure and reduced endothelium-dependent vasodilation, the
latter being reverted by NADPH oxidase blockade. Furthermore, vascular remodeling and stronger
Masson trichrome staining, together with enhanced immunofluorescence signal for collagen 1 alpha
1 (Col1α1), were observed in aortas from treated animals. These results were accompanied by a
significant elevation in superoxide anion production and the activity/protein/gene expression of
NADPH oxidase isoforms (NOX1, NOX2, and NOX4), which was also prevented by NOX inhibition.
Furthermore, a decrease in nitric oxide (NO) levels and endothelial nitric oxide synthase (eNOS)
activation was observed in aortas from Su-treated animals. All these results indicate that endothelial
dysfunction secondary to changes in vascular remodeling and oxidative stress might be responsible
for the typical arterial hypertension that develops following treatment with Su.
Keywords: arterial hypertension; endothelial dysfunction; tyrosine kinase inhibitor;
vascular remodeling
1. Introduction
Antiangiogenic treatment with tyrosine kinase inhibitors (TKIs) has been widely used in cancer
therapy in the last years [1]. TKIs effect consist of competing with ATP for the ATP-binding site
on protein tyrosine kinases, thus decreasing phosphorylation and cancer cell proliferation. TKIs
inhibit epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and
vascular endothelial growth factor receptor (VEGFR). The variety of commercially available TKIs has
improved the therapeutic management of cancer in the last decades. However, these drugs are often
associated with adverse side effects, including cardiovascular toxicity and arterial hypertension [2].
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Sunitinib (Su) is an orally active multitarget TKI accepted by the U.S. Food and Drug Administration
(FDA) and by the European Commission [3]. Su is the first-line choice for metastatic renal cell
carcinoma treatment and the second-line one for gastrointestinal stromal tumors (GISTs) and pancreatic
neuroendocrine tumors [4,5]. This compound binds to several tyrosine kinase receptors including
VEGFR, PDGFR, and the stem cell factor receptor (c-KIT). Similar to other VEGFR inhibitors, arterial
hypertension is a common feature associated with Su treatment [6]. Although several mechanisms
have been suggested to explain this side effect, the underlying pathophysiological mechanism remains
unknown. Reduced nitric oxide (NO) generation, endothelial dysfunction, and capillary rarefaction
have been proposed as factors involved in anti-VEGF-induced arterial hypertension [7,8]. Su-induced
arterial hypertension has also been related to an increase in endothelin-1 (ET-1) levels [9], and the
administration with the ET-1 receptor antagonist macitentan showed attenuation in the elevation of
blood pressure [10]. However, these results were not reproduced with bosentan, another blocker of the
ET-1 receptor [11]. Additionally, stiffness of large arteries, changes in arterial mechanical properties
and fibrosis have been implicated in blood pressure elevation secondary to treatment with TKIs [12,13],
suggesting that local vasoconstriction in specific areas might be responsible for the onset of arterial
hypertension [11].
Other investigators, in addition to our previous work, have demonstrated that enhanced oxidative
stress is one of the relevant alterations in hearts from Su-treated rats, suggesting the important role of
reactive oxygen species (ROS) in the vascular dysfunction and hypertension processes surrounding
TKI-induced cardiotoxicity [14–16]. Our present work furthers our understanding of the possible
mechanisms involved in arterial hypertension secondary to treatment with Su. To this purpose,
histomorphometric studies were carried out in aortas from Su-treated rats, to check this tissue for
vascular remodeling and analyzing the location of type I collagen as a final product of fibrosis. In
addition, superoxide anion (O2−) production, location, activity, and expression of ROS-generating
nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), NO levels, endothelial nitric
oxide synthase (eNOS) protein/mRNA expression, together with vascular reactivity experiments, were
performed in aortas from Su-treated animals and compared with non-treated normotensive Wistar rats.
2. Materials and Methods
2.1. Animals and Experimental Design
Male Wistar rats (8–10 weeks old) were supplied by the Center for Animal Production and
Experimentation (University of Seville, Spain) and kept under standard conditions (23 ± 1 ◦C, 12h/12h
light/dark cycles). All procedures complied with the European Union (EU Directive 2010/63/EU) and
the National (RD 53/2013) guidelines and were approved by the competent Institutional Animal Care
and Use Committee (approval reference #08/03/2017/034; date of approval: 08 March 2017, issued by
Junta de Andalucía, Dirección General de la Producción Agrícola y Ganadera). Two groups of 15 rats
each were randomly assigned to: (i) control group with free access to food and tap water; and (ii) rats
subjected to treatment with 25 mg Su/kg body weight/day for three weeks. An appropriate solution
of Su (Pfizer Inc, 2019) was prepared in tap water and homogenized mixed homogeneously within
crushed pellet to form Su-containing pellets. To ensure the correct dosage, the concentration of Su was
weekly adjusted according to each animal’s body weight and average daily food intake.
2.2. Blood Pressure and Tissue Preparations
During the experimental period, blood pressure, heart rate, and body weight were continuously
monitored, as previously described [14]. Upon treatment completion, animals were injected with
75 mg/kg ketamine + 10 mg/kg diazepam (i.p.), the intact thoracic aorta was removed and ice-cold 0.9%
saline solution was used to wash the tissue. The connective tissue around the aorta was removed and
the vessel was then cut into pieces. The superior portion (including the aortic arch) was immediately
frozen in liquid nitrogen and stored at −80 ◦C until use for detection of mRNA/protein expression. The
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rest was employed for functional studies (vascular reactivity) and dihydroethidium (DHE) assay and
histomorphometric studies. All animals were routinely sacrificed between 9:00 to 10:00 h to minimize
diurnal variation.
Aorta tissue was homogenized in radioimmunoprecipitation assay (RIPA) buffer with a
micro-pestle motor-driven tissue homogenizer (Heidolph Instruments, Schwabach, Germany) for
Western blot studies. After centrifugation at 2000× g for 10 min at 4 ◦C, the supernatant was stored
at −80 ◦C and the pellet was discarded. The Bradford method was used for determining protein
concentration [17] (Bio-Rad Protein Assay. Bio-Rad Laboratories, USA).
2.3. Measurement of the Levels of Superoxide Anion and Nitric Oxide Concentration
The superoxide-sensitive fluorescent dye dihydroethidium (DHE; MedChemExpress, HY-D0079)
was used to estimate the level of O2− as previously reported [18]. Thoracic aortas were embedded in
Tissue-Tek®O.C.T.™ (Sakura Finetek, 4583) and frozen sections were cut into 10 µm thick sections
with a cryostat (Leica CM1510 S, Leica Biosystems). Sections were thawed, incubated with DHE
(10 mM) at 37 ◦C for 10 min and with 4’,6-diamidino-2-phenylindole (DAPI) Fluoromount-G®
(SouthernBiotech, 0100-20). Serial sections were treated with either 10 µmol/L VAS2870 (pan-inhibitor
of NOX isoforms; Merk Millipore, 492000), 0.1 µmol/L GKT136901 (NOX1 and NOX4 inhibitor, Merk
Millipore, 5340320001), 0.5 µmol/L ML171 (specific NOX1 inhibitor; Sigma Aldrich, 175226); or 100
µmol/L L-NAME (eNOS inhibitor; Sigma-Aldrich, N5751) for 30 min prior to incubation with DHE.
Preincubation with 100 U/mL polyethylene glycol-conjugated SOD (PEG-SOD; Sigma Aldrich, S9549)
for 10 min at 37 ◦C was carried out to confirm the specificity of staining. All sections were examined
on a fluorescence microscope (Olympus BX61. Olympus Corporation) and photographed with a color
digital camera (Olympus DP73. Olympus Corporation). O2− production was estimated from the
ratio ethidium/DAPI fluorescence signal using ImageJ (Version 2.0.0-rc-69/1.52p. National Institutes
of Health, Bethesda, MD). Nitrite and nitrate levels in aorta homogenates were estimated by the
Griess method [19] in the absence and presence of NOX inhibitors in the same final concentration as
described above.
2.4. Measurement of NADPH Oxidase Activity
Aorta homogenates were used to determine NADPH oxidase activity by lucigenin-enhanced
chemiluminescence, as previously reported [20]. In order to confirm the isoform involved in the
production of superoxide anions (O2−), homogenate samples were preincubated for 5 min at 37 ◦C
with VAS2870, GKT136901, ML171, and L-NAME at the same final concentrations stated in Section 2.3.
2.5. RNA Extraction and Real-Time PCR
Frozen aortas were used to extract total RNA and retro-transcribed as previously described [21].
The generated cDNAs were used for real-time PCR with SYBR GreenTM (Roche, 04673514001) reactions
in a LightCycler1 480 Real-Time PCR System (Roche Diagnostics, Madrid, Spain). Primer sequences
(Biomedal, Seville, Spain) used in this study are detailed in Table 1, including glyceraldehyde
3-phosphate dehydrogenase (GAPDH) that was used as an endogenous control reference. Data were
analyzed and quantified with the 2−∆∆Ct method [22].
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Table 1. The primers used for real-time RT-PCR.
Gene Forward (5′–3′) Reverse (5′–3′)
Col1 TCAGGGGCGAAGGCAACAGT TTGGGATGGAGGGAGTTTACACGA
TGF-β1 GCCCTGGATACCAACTACTGCT AGGCTCCAAATGTAGGGGCAGG
NOX1 TTCACCAATTCCCAGGATTGAAGTGGATGGTC GACCTGTCACGATGTCAGTGGCCTTGTCAA
NOX2 CCCTTTGGTACAGCCAGTGAAGAT CAATCCCAGCTCCCACTAACATCA
NOX4 TTGCTTTTGTATCTTC CTTACCTTCGTCACAG
eNOS GGGCCAGGGTGATGAGCTCTG CCCTCCTGGCTTCCAGTGTCC
GAPDH GCCAAAAGGGTCATCATCTCCGC GGATGACCTTGCCCACAGCCTTG
Notes: Collagen type I (Col1), transforming growth factor β (TGF-β1), NADPH oxidase isoforms (NOX1, NOX2,
and NOX4), endothelial nitric oxide synthase (eNOS), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
2.6. Western Blotting
Following SDS-PAGE, proteins were transferred to nitrocellulose membrane and incubated with
specific antibodies: mouse monoclonal anti-TGF-β1 (3C11) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA; 1:3000 dilution); rabbit polyclonal anti-MOX1 (H-75) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA; 1:1000 dilution); rabbit monoclonal anti-NOX2 (Epitomics-Abcam, Burlingame, CA, USA; 1:8000
dilution); rabbit monoclonal anti-NOX4 (Epitomics-Abcam, Burlingame, CA, USA; 1:7500 dilution);
mouse monoclonal anti-NOS3 (A-9) (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:2000 dilution);
purified mouse anti-eNOS (pS1177) (BD Transduction Laboratories, 1:2000 dilution); mouse monoclonal
anti-p-NOS3 (pt495.33) (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:2000 dilution); mouse
monoclonal anti-3-nitrotyrosine (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:1000 dilution).
Mouse monoclonal anti-β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:20,000 dilution)
was also used for protein loading control. Adequate anti-rabbit or anti-mouse secondary antibodies
were used following the manufacturer’s recommendations, and signals were revealed with ECL™
Prime Western Blotting System (Amersham, RPN2232) and measured with an Amersham Imager 600
(GE Healthcare Life Science).
2.7. Vascular Reactivity
Vascular function was carried out as previously reported [23] using a Panlab organ bath (Harvard
Apparatus) and a PowerLab® 8/30 data acquisition system (ADInstruments) coupled to appropriate
transducers and controlled by the LabChartTM software (ADInstruments). Endothelium-intact aortic
rings were contracted with 10−9–3×10−5 mol/L phenylephrine (Phe) and relaxed with 10−9–3×10−5
mol/L acetylcholine (ACh) or 10−10–3×10−6 mol/L sodium nitroprusside (SNP). Selective NOX1 inhibitor
ML171 (2-acetylphenothiazine) and eNOS inhibitor (L-NAME) were preincubated at 10−4 mol/L.
2.8. Histomorphometric Studies
Slices from thoracic aortas were stained with hematoxylin and eosin and photographed with an
Olympus BX41 microscope. The area and thickness of tunica media and the lumen area were calculated
using Image J (Version 2.0.0-rc-69/1.52p. National Institutes of Health, Bethesda, MD). Additional slices
were stained with Masson’s trichrome to determine qualitative total collagen content following the
instructions from the Sigma-Aldrich kit HT15-1KT. Images were captured and processed with bright
field of the microscope Zeiss Axio Observer Z1 using bright field and the 10× objective.
2.9. Immunofluorescence Studies
Double immunofluorescence was carried out on frozen sections using the following antibodies:
α-smooth muscle actin-Cy3 (α-SMA) (Sigma Aldrich, 1:1000 dilution); sheep polyclonal anti-Collagen
1α1 (Alexa Fluor; 1:200 dilution); rabbit polyclonal anti-CD31 (Epitomics-Abcam, Burlingame, CA,
USA; 1:100 dilution); rabbit polyclonal anti-MOX1(H-75) (Santa Cruz Biotechnology, Santa Cruz,
CA, USA; 1:200 dilution); goat polyclonal anti-CD31/PECAM-1 (Alexa Fluor; 1:500 dilution). After
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incubation, sections were treated with appropriate anti-rabbit, anti-goat or anti-sheep fluorescent
secondary antibodies. Nuclei were also stained with DAPI during secondary antibody incubation.
Random aortic rings were captured and processed with a Zeiss Axio Observer Z1 Inverted Phase
Contrast Fluorescence Microscope using the 20×, 40× or oil 100× objective.
2.10. Statistics
Results were evaluated using GraphPad Prism version 5.01 (GraphPad Software Inc., San Diego,
CA, USA, 2007) and expressed as the mean ± S.E.M. Differences in mean values between groups were
analyzed with the unpaired, two-tailed Student’s t-test and considered statistically different at p < 0.05.
Data from ACh-mediated vasodilation, including preincubation with ML171, DHE, NADPH oxidase,
and NO assays were analyzed by one-way ANOVA followed by the Tukey’s multiple comparisons test
and considered statistically different at p < 0.05.
3. Results
3.1. General Characteristics of Animals
Upon three-week experimental period completion, a significant decrease in weight gain was
observed in treated animals when compared with control group (Figure 1A), despite no changes
in food/water intake between both groups of study (Figure 1B,C). In addition, Su-treated animals
presented with enhanced final blood pressure values (Figure 1D,E). On the other hand, heart rate
values were similar in both groups (Figure 1F).
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Figure 1. (A) Weight gain, (B) food intake, (C) water intake, (D) systolic blood pressure, (E) diastolic
blood pressure, and (F) heart rate in control and sunitinib (Su)-treated (25 mg/kg/day) animals. Values
are expressed as mean ± S.E.M. of 15 animals per group. ** p < 0.01, *** p < 0.001 vs. control group.
3.2. Endothelial Dysfunction in Su-treated Rats
Vascular reactivity st ies s e no changes between both groups of rats regarding
the vasoconstrictor response to phenylephrine (Phe) (Figure 2A). On the other hand,
endothelium-dependent vasodilation in response to acetylcholine (ACh) was significantly lower
in aortic rings from treated animals (Figure 2B); thus, a significant decrease in h-i ce maximal
vasorelaxation response (Emax) was observed in this group when compared with the contr l group (63
± 3.8% vs. 106 ± 1.7%, respectively; p < 0.01). In contrast, EC50 values for ACh-induced vasodilation
were similar in both experimental groups (7.72 ± 0.06 vs. 7.76 ± 0.24 for control and Su, respectively).
Interestingly, when aortic rings from Su-treated rats were preincubated with ML171 (an inhibitor of
NOX1 isoform of NADPH oxidase), the Emax for endothelium-dependent relaxation reached values
similar to those of the control group (95.3 ± 2.98%), while EC50 was unaffected by the inhibitor (7.36 ±
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0.11). When studies on ACh-induced vasodilation were done in the presence of 10−4 mol/L L-NAME
(Nω- nitro-L-arginine methyl ester, an inhibitor of NO synthesis), Emax values dropped to similar levels
in both cases (44 ± 2.88% and 32.3 ± 1.93% for control and treated rats, respectively; Figure 2C). Results
concerning endothelium-independent vasorelaxation did not show changes between control and Su
groups in either Emax (109 ± 2.4% vs. 118.5 ± 3.1%) or EC50 (8.7 ± 0.09 vs. 8.9 ± 0.09) parameters in
response to nitric oxide donor sodium nitroprusside (SNP; Figure 2D).
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Figure 2. Dose-response curve of (A) vasoconstriction mediated by phenylephrine (Phe) (10−9–3 × 10−5
mol/L); (B) ACh-mediated (10−9–3 × 10−5 mol/L) vasodilation, including preincubation with ML171
(10−4 mol/L); (C) ACh-mediated vasodilation in the presence of L-NAME (Nω- nitro-L-arginine methyl
ester (10−4 mol/L); and (D) vasorelaxation response to sodium nitroprusside (SNP) (10−10–3 × 10−6
mol/L) in phenylephrine (Phe)-precontracted vessels from control and sunitinib-treated (25 g/kg/day)
ani als. The results correspond to ean ± S.E. . of at least six experiments (n = 6–12). esults are
expressed as relative percentages of the maximum contraction induced by 60 mmol/L KCl (A), or to the
contraction induce by a submaxi al dose of Phe (B–D). ** p < 0.01; *** p < 0.001 vs. control group, # p
< 0.05, ## p < 0.01, ## p < 0.0 1 vs. Su group.
3.3. Vascular Remodeling and Fibrosis
orpho etric studies revealed that the thickness of tunica media (Figure 3A,B) and the
cross-sectional area (CSA; Figure 3C) increased in Su-treated rats when compared with control
rats. Since the luminal area showed no changes between groups (Figure 3D), a rise in the edia/lumen
ratio was found in Su-treated rats (Figure 3E), thus indicating the presence of vascular remodeling in
these hypertensive animals.
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The Masson’s trichrome staining showed a slightly intensified blue coloration in aortas from
treated rats, revealing an increased total content of collagen (Figure 4A,B). Collagen 1 alpha 1 (Col1α1)
isoform is per se expressed in the outer layer of the aortic vascular tissue in both groups, mostly in
the adventitia (Figure 4C,D). Nevertheless, aortic rings from Su-treated rats also showed an intense
immunofluorescence staining with collagen deposition in the media and intima layer (basement
membrane and the extracellular matrix of endothelial cells) (Figure 4E–H). In addition, the mRNA
expression of Col1 and the protein and gene expression of TGF-βwere also increased in aortas from
treated rats (Figure 4I–K), thus suggesting a correlation between Col1α1 immunofluorescence and the
expressions of these fibrosis-related components.
3.4. Assessment of Vascular Oxidative Stress
Dihydroethidium (DHE) imaging showed an increase in superoxide anion (O2−) production in
the aortas of rats subjected to treatment with Su compared to the control group (Figure 5). When aortic
ring preparations were preincubated with polyethylene glycol-superoxide dismutase (PEG-SOD, DHE
staining disappeared and confirmed the presence of O2−. Preincubating aortic segments from Su-treated
animals with NADPH oxidase inhibitors, namely ML171, GKT136901, and VAS2870, attenuated the
superoxide anion formation back to levels measured in the control group. On the other hand, no
change in O2− production was observed following incubation of rings from Su-treated animals with
the eNOS inhibitor, L-NAME (Figure 5A,B).
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6–8). * p < 0.05; ** p < 0.01; *** p < 0.001 vs. control group.
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Figure 5. Superoxide anion production in thoracic aortas. (A) Representative dihydroethidium (DHE)
staining, (B) superoxide anion quantification, (C) NADPH oxidase activity in aorta homogenates, and
(D) 3-nitrotyrosine protein expression, in aortas from control and sunitinib-treated (25 mg/kg/day)
animals. Magnification: 10×. Values are expressed as mean ± S.E.M. of at least four animals per group
(n = 4–8). * p < 0.05, *** p < 0.001 vs. control group; ## p < 0.01, ### p < 0.001 vs. Su group; ++ p < 0.01,
+++ p < 0.001 vs. Su + ML171 group; ººº p < 0.001 vs. Su + GKT136901 group; yyy p < 0.001 vs. Su +
VAS2870 group.
The activity of NADPH oxidase was increased in aortas from Su-treated rats compared to the
control group (Figure 5C). Again, NOX inhibitors reduced the activity of the enzyme in aortas from
Su-treated rats in a similar manner as observed with DHE staining. In contrast, L-NAME had no
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effect on NADPH oxidase activity in Su-treated rats. These results were accompanied by a significant
increase in the protein expression of the oxidative stress biomarker, 3-nitrotyrosine, in aortas from
Su-treated rats compared to the control group (Figure 5D).
The double immunofluorescence staining of NOX1 isoform of NADPH oxidase (red) andα-smooth
muscle actin (α-SMA) (green) showed that NOX1 is located in VSMCs and the adventitia from control
aortas and Su-treated animals, with a stronger co-localization in the latter (Figure 6A–D). The
double immunostaining of NOX1 (red) and CD31 (green) showed the co-localization of NOX1 within
endothelial cells in aortas from Su-treated rats (Figure 6E–H). Therefore, an increase in the presence
of NOX1 was observed in all three vascular layers in aortas from rats subjected to treatment with Su.
These results correlated with a rise in the gene and protein expression of NOX1 and NOX2 in aortas
from Su-treated (Figure 6I,J). As for the isoform NOX4, although hypertensive animals also showed an
upregulation in the gene expression of this NADPH isoform, no changes were observed between both
groups in the relative amount of protein estimated from Western blot analysis (Figure 6K).FIGURE 6
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K
Figure 6. Double immunostaining of NOX1 (red) and α-SMA (VSMCs) (green) (A–D), and NOX1
(red) and CD31 (green) (E–H), in aortas from control and sunitinib-treated (25 mg/kg/day) animals.
Magnifications: 40× (A,C,E,G) and 100× (B,D,F,H). (I–K) Protein and mRNA expression of NOX1 (I),
NOX2 (J), and NOX4 (K). Values are expressed as mean ± S.E.M. of eight animals per group. * p < 0.05;
*** p < 0.001 vs. control group.
Additional experiments revealed a decline in total eNOS protein expression (Figure 7A,B) and
phosphorylation of eNOS at Ser1177 and Thr495 (Figure 7A) in Su-treated group. When the ratio p-Ser1177
eNOS/total eNOS and p-Thr495 eNOS/total eNOS was determined, a reduction in both parameters was
measured in rats subjected to treatment with Su (Figure 7C,D). Furthermore, the gene expression of
eNOS was increased in this group of hypertensive animals (Figure 7E). NO levels showed a decrease
in aorta homogenates from Su-treated animals, which was reverted to control levels by preincubation
with NOX inhibitors (Figure 7F).
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Figure 7. Protein expression of (A) p-endothelial nitric oxide synthase (eNOS) (Ser1177) and p-eNOS
(Thr495); (A,B) total eNOS (t-eNOS); (C) ratio p-eNOS (Ser1177)/total eNOS; (D) ratio p-eNOS
(Thr495)/total eNOS; (E) t-eNOS mRNA expression; and (F) NO levels in absence or presence of
NOX inhibitors, in aortas from control and sunitinib-treated (25 mg/kg/day) animals. Values are
expressed as mean ± S.E.M. of eight animals per group. * p < 0.05; ** p < 0.01; *** p < 0.001 vs.
control group.; ### p < 0.001 vs. Su group; + p < 0.05 vs. Su + ML171 group; ºº p < 0.01 vs. Su +
GKT136901 group.
4. Discussion
Multiple studies have shown a clear correlation between TKIs therapy and the development of
cardiovascular toxicity, including arterial hypertension as a common side effect of VEGF inhibitors
used in cancer medicine [2]. We and others have focused on enhanced oxidative stress as an important
component of cardiotoxicity induced by either Su [14,16], or other TKIs such as VEGFR inhibitor
vatalanib and EGFR inhibitor gefitinib [15]. However, since the factors underlying Su-induced arterial
hypertension remain unknown [24], here we aimed to gain further knowledge on possible mechanisms
triggering Su-induced vascular damage.
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Su is administered orally and is used as a first-line treatment in adults with metastatic renal cell
carcinoma (mRCC) [5]. The current study was designed in male rats due to the higher frequency of
mRCC in men compared with women [25]. In addition, the terminal half-life after oral administration of
Su was similar in female and male rats [26]. Our results are in agreement with several studies reporting
the use of various antitumor agents [27,28]. Thus, weight gain was negatively affected by Su treatment,
although food and water intake remained the same in both experimental groups. Increased levels in
systolic and diastolic blood pressures were observed in Su-treated animals, a common feature also
observed with other inhibitors of angiogenesis, such as sorafenib (VEGFR inhibitor) and bevacizumab
(monoclonal antibody against VEGF) [29–31]. On the other hand, other TKIs such as vatalanib and
gefitinib (respective VEGFR and EGFR inhibitors) did not induce hypertension in treated mice [15].
Our results did not show differences in heart rate between control and rats treated with Su for 21
days. Similar results were found by Blasi et al. [29] in rats in the first 28 days of treatment with Su. On
the other hand, other studies reported either increased [14] or decreased [32,33] heart rate following Su
treatment, which suggests that these differences might be related to changes in dosing and/or duration
of treatment.
The hypertensive mechanisms related to Su therapy might be directly associated with its inhibitor
effect on vascular endothelial growth factor (VEGF) signal pathways, leading to density-reduced
microvessels, reduced NO production associated with endothelial dysfunction, and enhancement of
oxidative stress [14]. A reduction in NO bioavailability might also be due to an imbalance between
vasodilator (NO) and vasoconstrictor (ET-1) molecules in favor of the latter [9]. In addition, previous
studies in humans reported that polymorphisms of genes such as VEGFA, VEGFR-2, ET-1, and eNOS
might predispose to hypertension after Su treatment [34]. Our studies demonstrated a reduction in
endothelium-dependent vasodilation in treated animals when compared with normotensive control
animals, an observation that was abolished after the addition of NOX1 inhibitor ML171. This finding
suggests a major contribution of NOX1 isoform in the endothelial dysfunction induced by Su. The
presence of L-NAME (an inhibitor of eNOS) produced a lower response to ACh in both experimental
groups up to a similar extent, and no changes were observed with endothelium-independent
vasorelaxation with SNP. Similar results were observed by Thijs et al. [27] and Neves et al. [15]
in mesenteric arteries from Su-treated rats and mesenteric arteries from mice incubated with vatalanib,
respectively. Nevertheless, the incubation of mice mesenteric arteries with EGFR inhibitor gefitinib did
not show changes in the vascular response to ACh [15].
In agreement with our results, Thijs et al. [25] found that the differences observed in the
ACh-induced response between control and Su-treated animals was eliminated in the presence of
L-NAME. This indicates that a reduction in NO bioavailability in Su-treated rats might be responsible
for the high blood pressure observed in these animals. However, since the presence of L-NAME
produced a further slight decrease in ACh-induced vasorelaxation than that observed with Su treatment
alone, factors other than NO might also play a role in the genesis of hypertension in the context of Su
treatment; these factors include oxidative stress, ET-1, and gene polymorphisms [15,34]. The fact that
endothelium-independent vasorelaxation was unaffected indicates that Su effect on vascular function
occurs in an endothelium-dependent manner.
Structural vascular modifications were also found in our study. Thus, thickness, CSA, and
media/lumen ratio were significantly increased in thoracic aortas from Su-treated rats. Regarding the
classification described by Renna et al. [35], these results indicate that severe hypertrophic vascular
remodeling appears in the aorta of Su-treated rats when compared with control animals. These results
are in agreement with previous studies in mesenteric arteries from mice treated with vatalanib, in
which an increased media/lumen ratio was exhibited [15]. On the other hand, the use of gefitinib had
no effect on cross-sectional area [15]. Reductions in the diameter and vasoconstriction of mice [27] and
rat [11] mesenteric arteries, together with stiffness and fibrosis in human large arteries [12], have been
observed after treatment with Su and other VEGF inhibitors.
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Vascular wall remodeling processes involve changes in growth and migration of VSMCs,
endothelial dysfunction, inflammatory processes, and changes in extracellular matrix components
(EMCs) [35]. In this way, collagen types I and III are the main isoforms in adventitia [36], while collagen
I, III, and V are mainly present in media layer [37]. Positive staining for Col1α1 immunofluorescence
was found in the adventitia and media layer of both groups of animals. In the media layer from the
Su-treated animals, the staining of Col1α1 was intense compared with control rats. However, only
in the intima layer of Su-treated rats, intense Col1α1 staining was found. This difference of Col1α1
staining between both groups of animals might be due to changes in the collagen composition as
a consequence of the treatment of Su since modifications in the quantity and location of collagen
fibers seem to appear in aorta diseases [38]. On the other hand, there is no evidence concerning the
presence of collagen type I in the inner layer. However, the deposition of collagen type I was observed
in our study in the basement membrane of Su-treated aorta when compared with the control group.
These collagen fibers might interpose between endothelial cells and the middle layer, thus causing an
increase in aorta thickness. The increase in Col1α1 staining observed in rats subjected to Su treatment is
supported by the enhancement in the total content of collagen and upregulation of profibrotic cytokine
TGF-β1 and collagen type I in these animals. Previous studies in our lab showed a rise in the expression
of collagen type I, TGF-β1, and tissue inhibitor matrix metalloproteinases (TIMP-1) accompanied by a
decrease in that of matrix metalloproteinase (MMP-9) in heart tissue from Su-treated rats [14]. Based
on these results, changes in enzymes involved in the turnover of collagen might also be affected in
aortas from rats treated with Su.
As previously reported, oxidative stress is one of the mechanisms involved in the synthesis of ECM
and accumulation of collagen fiber in the intima layer during the process of vascular remodeling [39,40],
where an increase of pro-oxidant species together with a reduction in endothelial NO production is
observed [41]. The most widely used method to quantify cellular O2− in mammalian cells is based
on DHE staining. MitoSOX or HPLC are currently being used for mitochondrial O2− detection,
although one major limitation of the latter is the inability to distinguish the specific cells contributing
to ROS production in response to pathological stimuli [42]. In our study, we found an increase in
superoxide anion (O2−) content in the aorta of rats treated with Su compared with the control group.
Interestingly, the use of commercially available inhibitors of NOX isoforms, namely ML171, GKT136901,
and VAS2870, resulted in clearly visible and quantifiable reductions of O2− production in aortas from
Su-treated rats. Moreover, when NADPH oxidase activity (a pivotal enzyme for ROS production in
the hypertensive context) was determined by means of lucigenin-enhanced chemiluminescence, an
increase in the activity was found in aortas from Su-treated rats when compared to the control group,
which was also blocked via specific NOX inhibition. In contrast, the eNOS inhibitor, L-NAME, did
not affect superoxide release in Su-treated group. Taken together, these results revealed NOX1 as the
main isoform involved in the production of ROS in aorta from Su-treated animals, thus confirming the
results concerning endothelium-dependent vasodilation.
Neves et al. [15] previously demonstrated that vatalanib treatment induced activation of NADPH
oxidase in human aortic endothelial cells (HAECs) and mice kidney. However, the reported changes
were found following treatment with gefitinib, where the increased NADPH-dependent O2− generation
in HAECs by vatalanib is inhibited by a NOX1/4 inhibitor [15].
In additional experiments, we also found an enhancement in the protein expression of
3-nitrotyrosine, a stable byproduct whose production is modified in the context of oxidative stress [42],
in the aorta from Su-treated rats compared to the control group. Regarding specific changes in
the expression of NOX isoforms of NADPH oxidase, NOX1, NOX2, and NOX4 were upregulated
in Su-treated rats, although NOX4 showed no significant changes in the protein expression when
compared with non-treated animals. Previous studies also found modifications in the regulation of
NOX isoforms after treatment with such TKIs. An increase in mRNA expression of NOX1, together with
a decrease in the expression of NOX4, was found in heart and kidney, respectively, from mice treated
with vatalanib and gefitinib when compared with control animals, accompanied by no alterations
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in NOX2 levels in both tissues. When studies were carried out in vascular smooth muscle cells and
HAEC, differences were observed depending on the NOX isoforms and the source of TKI added in the
incubation medium [15]. In addition, an increase in NOX expressions was observed in the heart of
rats treated with Su [14]. All these findings suggest differential effects of TKIs on NADPH system;
however, despite specific differences observed in NOX isoform expression, an oxidative imbalance
is highly involved in arterial hypertension and toxicity produced by Su and other TKIs, including
VEGFR and EFGR inhibitors.
In our study, the presence of redox imbalance was supported by decreased NO levels measured
in aortas from Su-treated animals, where the use of NOX inhibitors increased the bioavailability of
NO over those values measured in the control group. These results concerning NO concentration
parallel the pattern observed for eNOS protein expression and activation, although animals subjected
to treatment with Su also showed an upregulation of total eNOS gene expression, interestingly.
5. Conclusions
Our study provides novel insights on the molecular mechanisms involved in the vascular damage
produced by treatment with the tyrosine kinase inhibitor, sunitinib (Su). As expected, Su administered
daily for three weeks led to development of arterial hypertension, which might be due to endothelial
dysfunction and vascular remodeling induced by the drug via overactivation of the NADPH oxidase
system (mainly via NOX 1 isoform) and, consequently, an alteration of the redox balance. We must
note, however, that the current data cannot ascertain whether arterial hypertension is secondary to
oxidative stress or due to direct vascular injury following Su treatment. In this sense, previous studies
in humans treated with Su demonstrated that endothelial dysfunction might be relevant in maintaining
(or further increasing) high arterial pressure but does not precede its initial development [27]. Another
limitation of our study is that histological and biochemical disturbances have been reported in aortic
tissue from Su-treated rats; further studies on resistant vessels (e.g., mesenteric arteries), will probably
help elucidate those vascular molecular mechanisms involved in Su-associated arterial hypertension.
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